Recent advances and research progress regarding monoclonal antibodies for chronic graft-versus-host disease
Shiqin Huang,
Xianjing Cheng,
Guancui Yang,
Ruihao Huang,
Yimei Feng,
Lingyu Zeng,
Tao Wu,
Qingxiao Song,
Xiaoqi Wang,
Xi Zhang
Affiliations
Shiqin Huang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China
Xianjing Cheng
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China
Guancui Yang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China
Ruihao Huang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China
Yimei Feng
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China
Lingyu Zeng
Blood Diseases Institute, Xuzhou Medical University, Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu, China
Tao Wu
Department of Hematology, Center of Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu, China
Qingxiao Song
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China; Corresponding author.
Xiaoqi Wang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China; Corresponding author. Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China.
Xi Zhang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037 China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037 China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China; Jinfeng Laboratory, Chongqing 400000, China; Corresponding author.
Chronic graft-versus-host disease (cGVHD) is one of the leading causes of mortality following allogeneic hematopoietic stem cell transplantation (HSCT), with only 50 % of patients responding to conventional corticosteroids with or without calcineurin inhibitors. Monoclonal antibodies (mAbs), such as CD20 mAbs, are the first drugs to demonstrate greater efficacy than corticosteroids in first-line treatment of cGVHD. This review provides a comprehensive overview of recent developments in the clinical utilization of mAbs to prevent and treat cGVHD. We also describe the application of drugs with target sites that are identical to or linked to those of cGVHD in autoimmune diseases as potential future treatments for cGVHD. In summary, we collected known evidence concerning the clinical research progress on the use of mAbs in the prevention and treatment of cGVHD and identified drugs with the same target sites in autoimmune diseases for potential future applications in cGVHD, with the goal of providing suggestions and inspiration for optimizing cGVHD treatment strategies and research directions.
